56/F | ACOM | 5.7 × 3.5 | 1 | P | No (80%)/3/2 | 5mg Abciximab IV, 500mg aspirin IV | Complete, immediate | Rupture | 6 |
68/M | ACOM | 5 × 3 | 1 | P | Yes/5/0 | 5mg Abciximab IV, 30mg Papavarine IA | Complete, immediate | None | 1 |
27/F | PCOM | 98 × 8 | 1 | P | Yes/5/0 | 5mg Abciximab IV | Partial, immediate | None | 1 |
63/M | ACOM | 6.5 × 7.5 | 2 | P | Yes/4/0 | 20mg of Abciximab IV,500mg aspirin IV | Partial,immediate | Shunt/haematomaevacuation | 4 |
72/F | PCOM | 2.2 × 3 × 2 | 2 | D | No (0%)/0/4 | 5mg Abciximab x2 IV,direct agitation ofbasilar thrombus | Partial,immediate | Cerebellarinfarct | 1 |
52/M | ACOM | 7 × 5 | 1 | P | No (60%)/4/0 | 5mg Abciximab IV ×2,500mg aspirin IV | Complete,immediate | None | 1 |
59/M | Basilar tip | 12 × 12 × 10 | 5 | D | No (20%)/6/0 | 10mg Abciximab IV | Complete,immediate | PCA infarct | 1 |
79/F | ACOM | 7 × 5.4 × 6.7 | 1 | D | Yes/4/0 | 7.5mg Abciximab IV | Complete,immediate | RightACAinfarct | 1 |
51/F | PCOM | 6.3 × 6 × 7 | 5 to 2 | P, D | Yes/13/0 | Abciximab 5mg IV | Complete,immediate | None | 1 |
70/M | MCA | 5 × 4 | 2 | D | Yes/4/0 | 5mg Abciximab IV,40mg Papavarine IA,5mg Abciximab IV,30mg Papavarine IA | Partial aftersecondAbciximabdose | Transienthemiparesis | 1 |
52/F | PCOM | 15 × 14 | 1 | P | No (90%)/13/3 | 500mg aspirin IV,Abciximab 5mg IV | Complete,immediate | Transienthemiparesis/dysphasia | 1 |
46/F | PICA | 2 × 5 × 2 | 1 | P | Yes/2/0 | Abciximab 5mg IV/500 mg aspirin IV | NA/prophylaxis | None | 1 |
29/F | PCOM | 9 × 7.6 | 2 | P | Yes/6/0 | Abciximab 5mg IV | Complete,immediate | Transient lefthemiparesis | 1 |